Physician profile
Nihal E Abdulla
NPI 1750585345
$45,965.46
in general payments reported to CMS, 2019-2025
100 companies · $9,150 in 2025
The $9,150 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,342 · 2020: $2,704 · 2021: $9,081 · 2022: $4,858 · 2023: $7,919 · 2024: $9,911 · 2025: $9,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $8,773 · Education: $484 · Long Term Medical Supply Or Device Loan: $299 · Travel and Lodging: $60.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,364.13 |
| Consulting Fee | $8,772.50 |
| Education | $484.10 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Travel and Lodging | $60.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,192.55 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $4,021.87 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Jazz Pharmaceuticals INC. | $3,980.16 | 2021-2025 | |
| Beigene USA, INC. | $2,237.75 | 2023-2025 | Brukinsa |
| Pfizer INC. | $1,676.38 | 2019-2025 | |
| Celgene Corporation | $1,496.95 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $1,473.95 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,467.26 | 2019-2025 | |
| Incyte Corporation | $1,373.97 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $1,219.77 | 2019-2025 | Kyprolis, Blincyto, Nplate |
| E.R. Squibb & Sons, L.L.C. | $1,151.12 | 2019-2025 | Opdivo, Opdualag |
| Janssen Scientific Affairs, LLC | $1,138.32 | 2023-2025 | Rybrevant, Erleada, Akeega |
| Abbvie INC. | $841.15 | 2019-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $782.50 | 2019-2025 | |
| Genzyme Corporation | $763.64 | 2019-2025 |
Show all 98 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $643.79 | 2019-2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $626.12 | 2019-2025 | Polivy, Tecentriq, Phesgo |
| Regeneron Healthcare Solutions, INC. | $552.63 | 2020-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $543.90 | 2021-2025 | Fotivda |
| Lilly USA, LLC | $538.41 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $532.45 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Eisai INC. | $482.53 | 2019-2025 | |
| Gilead Sciences, INC. | $469.38 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $465.50 | 2019-2024 | Xtandi, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $422.86 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Janssen Pharmaceuticals, INC | $419.10 | 2019-2021 | |
| Array Biopharma INC | $399.21 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Seagen INC. | $395.03 | 2019-2023 | Tukysa, Adcetris |
| Cardinal Health 110 LLC | $388.01 | 2023-2025 | |
| Daiichi Sankyo INC. | $378.11 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Karyopharm Therapeutics INC. | $370.03 | 2021-2025 | Xpovio |
| Exelixis INC. | $356.73 | 2019-2025 | Cabometyx |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Sobi, INC | $346.78 | 2023-2025 | |
| Puma Biotechnology, INC. | $330.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.80 | 2019-2025 | Gilotrif |
| Kite Pharma, INC. | $296.13 | 2020-2024 | Yescarta |
| Alexion Pharmaceuticals, INC. | $284.11 | 2019-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $263.42 | 2023-2025 | Besremi |
| Emd Serono, INC. | $260.61 | 2019-2025 | Bavencio |
| Modernatx, INC. | $250.00 | 2022 | |
| Blueprint Medicines Corporation | $224.31 | 2020-2024 | Ayvakit |
| Sumitomo Pharma America, INC. | $210.64 | 2023-2025 | Orgovyx |
| Heron Therapeutics, INC. | $203.37 | 2020-2022 | |
| Stemline Therapeutics INC. | $201.00 | 2022-2025 | Orserdu, Elzonris |
| Novocure Gmbh | $200.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $193.73 | 2020-2025 | Onivyde, Somatuline Depot |
| Organon LLC | $163.20 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $150.42 | 2020-2025 | Rezlidhia, Gavreto, Tavalisse |
| Spectrum Pharmaceuticals INC. | $142.74 | 2024-2025 | Rolvedon |
| Taiho Oncology, INC. | $139.17 | 2021-2025 | |
| Adc Therapeutics America, INC. | $131.69 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $130.56 | 2019-2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $123.31 | 2021-2025 | Qinlock, Romvimza |
| Sun Pharmaceutical Industries INC. | $122.08 | 2023-2024 | Odomzo, Yonsa |
| Pharmacosmos Therapeutics INC. | $121.76 | 2023-2025 | Monoferric, Cosela |
| Springworks Therapeutics, INC. | $119.37 | 2024-2025 | Ogsiveo |
| Baxter Healthcare | $117.99 | 2019 | |
| Tempus Ai, INC | $109.71 | 2024 | Xt Cdx |
| Coherus Oncology, INC. | $107.18 | 2022-2025 | Loqtorzi |
| Accord Healthcare, INC. | $93.44 | 2025 | |
| Genmab U.S., INC. | $90.08 | 2023-2025 | Epkinly |
| Immunocore Limited | $84.48 | 2024-2025 | Kimmtrak |
| Global Blood Therapeutics, INC. | $75.83 | 2021-2022 | |
| Morphosys, US INC. | $69.47 | 2022-2023 | Monjuvi |
| Mirati Therapeutics, INC. | $69.46 | 2023-2024 | Krazati |
| Myovant Sciences INC. | $67.76 | 2021-2022 | |
| Immunogen, INC. | $57.20 | 2023-2024 | Elahere, Elahere |
| Kyowa Kirin, INC. | $56.23 | 2020-2025 | Poteligeo |
| Boston Scientific Corporation | $55.34 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Covidien Lp | $55.06 | 2019 | |
| Tersera Therapeutics LLC | $49.05 | 2023 | Quzyttir |
| Recordati_rare_diseases_inc. | $47.53 | 2023 | Sylvant |
| Servier Pharmaceuticals LLC | $44.60 | 2022 | |
| Cti Biopharma Corp. | $42.21 | 2023 | Vonjo |
| Eusa Pharma (US) LLC | $40.22 | 2020-2022 | |
| Dova Pharmaceuticals | $38.85 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $34.28 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $32.89 | 2019-2025 | Akynzeo |
| Azurity Pharmaceuticals, INC. | $32.52 | 2025 | Danziten |
| Geron Corporation | $29.91 | 2025 | Rytelo |
| Chiesi USA, INC. | $28.84 | 2023-2025 | Ferriprox |
| Sirtex Medical INC | $28.68 | 2024 | Sir-Spheres Microspheres |
| Tesaro, INC. | $28.63 | 2019 | |
| Syndax Pharmaceuticals, INC. | $25.82 | 2025 | |
| Myriad Genetic Laboratories, INC. | $25.40 | 2021 | |
| Beone Medicines USA, INC. | $25.32 | 2025 | Brukinsa |
| Iovance Biotherapeutics, INC. | $24.94 | 2025 | Amtagvi |
| Catalyst Pharmaceuticals, INC. | $24.02 | 2023 | Firdapse |
| Alnylam Pharmaceuticals INC. | $24.00 | 2025 | Givlaari |
| Epizyme, INC. | $23.58 | 2021 | |
| Mylan Institutional INC. | $23.23 | 2023 | Ogivri, Fulphila |
| Amneal Pharmaceuticals LLC | $20.71 | 2025 | Pemrydi Rtu |
| Adaptive Biotechnologies Corporation | $19.44 | 2024 | Clonoseq |
| Acceleron Pharma, INC. | $19.44 | 2020 | |
| Avyxa Pharma, LLC | $17.99 | 2025 | |
| G1 Therapeutics, INC. | $16.07 | 2023 | Cosela |
| Progenics Pharmaceuticals, INC. | $14.24 | 2023 | Pylarify |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$480.95 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nihal Abdulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.